Prospective Incidence of Paediatric Inflammatory Bowel Disease in New Zealand in 2015

Lopez, Robert; Evans, Helen; Appleton, Laura; Bishop, Jonathan; Chin, Simon; Mouat, Stephen; Gearry, Richard B.; Day, Andrew S.

doi:10.1097/mpg.0000000000001806

Cited by 20 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yap et al[ 26 ] calculated the incidence of IBD, CD and UC to be 2.9, 1.9 and 0.5/100000, respectively in NZ, which is at the lower end compared with the incidence in Europe. Recently, Lopez et al[ 160 ] provided important data pertaining to the incidence of pediatric IBD in NZ. The incidence of IBD, CD, UC and IBD-U in NZ in 2015 were 5.2, 3.5, 1.0 and 0.7/100000, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current global trends in the incidence of pediatric-onset inflammatory bowel disease

Sýkora

Pomahačová

Kreslová

et al. 2018

WJG

292

202

View full text Add to dashboard Cite

AIMTo perform a comprehensive review and provide an up-to-date synopsis of the incidence and trends of inflammatory bowel disease (IBD).METHODSWe systematically searched the MEDLINE (source PubMed), EMBASE and Cochrane Library databases in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (period: 1985-2018) to identify studies reporting population-based data on the incidence of pediatric-onset (< 19 years at diagnosis) IBD in full manuscripts. Two authors carried out screening and data extraction. Choropleth interactive maps and temporal trends were used to illustrate the international differences and incidences of and changes in IBD and subtypes.RESULTSIn total, one hundred forty studies reporting data from 38 countries were considered in this review. The highest annual pediatric incidences of IBD were 23/100000 person-years in Europe, 15.2/100000 in North America, and 11.4/100000 in Asia/the Middle East and Oceania. The highest annual incidences of Crohn’s disease (CD) were 13.9/100000 in North America and 12.3/100000 in Europe. The highest annual incidences of ulcerative colitis (UC) were 15.0/100000 in Europe and 10.6/100000 in North America. The highest annual incidences of IBD-unclassified (IBD-U) were 3.6/100000 in Europe and 2.1/100000 in North America. In the time-trend analyses, 67% of CD, 46% of UC and 11% of IBD-U studies reported an increasing incidence (P < 0.05). The risk of IBD is increasing among first-generation of migrant populations.CONCLUSIONGlobally, the incidence of IBD varies greatly by geographical areas. The steadily increasing incidence of pediatric IBD over time indicates its emergence as a global disease, suggesting that studies should investigate the environmental risk factors among pediatric cohorts.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A 4-fold increase was observed in the incidence of childhood IBD in the Canterbury Province of NZ between 1996 and 2015. The annual incidence rate was 7.18/100000 with the preponderance of CD over UC (8.4:1)[ 160 , 161 ].…”

Section: Discussionmentioning

confidence: 99%

Current global trends in the incidence of pediatric-onset inflammatory bowel disease

Sýkora

Pomahačová

Kreslová

et al. 2018

WJG

292

202

View full text Add to dashboard Cite

show abstract

“…The increasing incidence of IBD worldwide pressures healthcare systems to meet the needs of the increasing number of patients with IBD [ 18 ]. Increasing rates of IBD have been noted in children in New Zealand [ 19 , 20 ]. Reducing the DD could be one way of decreasing this burden [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Delay in Paediatric Inflammatory Bowel Disease—A Systematic Investigation

Khalilipour

Day

Kenrick

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Diagnostic delays (time from the first symptoms to diagnosis) are common in inflammatory bowel disease (IBD) and may lead to worse disease progression and treatment outcomes. This study aimed to determine the duration of diagnostic delays (DD) and to explore associated factors in a cohort of children with IBD in New Zealand. In this study, patients with IBD diagnosed as children and their parents/caregivers completed questionnaires on the patients’ medical history, diagnostic experience, and demographic characteristics. The parent/caregiver questionnaire also included the Barriers to Care Questionnaire (BCQ). Patients’ healthcare data was reviewed to summarise the history of clinical visits and determine symptoms. Total DD, healthcare DD, patient DD and parent DD were derived from the primary dataset. Factors associated with the different types of DD were explored with a series of simple linear and logistical ordinal regressions. A total of 36 patients (Crohn’s disease 25, ulcerative colitis 10; male 17) were included. They were diagnosed at a median age of 12 years (interquartile range (IQR) 10–15 years). Total healthcare delay (from first healthcare visit to formal diagnosis) was median (IQR) 15.4 (6.5–34.2) months. The median (IQR) specialist-associated delay was 4.5 (0–34) days. Higher household income was associated with shorter healthcare delay (p < 0.018), while lower overall BCQ scores (indicating more barriers experienced) were associated with longer total healthcare DD. Higher scores in each subscale of BCQ (Skills; Pragmatics; Expectations; Marginalization; Knowledge and Beliefs) were also significantly associated with shorter total healthcare delay (p < 0.04). This study found substantial diagnostic delays in paediatric patients with IBD and identified significant associations between longer total healthcare diagnostic delays and overall household income and higher self-reported barriers to accessing healthcare.

show abstract

“…Inflammatory bowel disease (IBD), which includes Crohn disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD‐U), is a chronic relapsing inflammatory condition involving the gastrointestinal tract (GIT) and extraintestinal manifestations 1 . The disease prevalence is high among western countries, including New Zealand (NZ), where incidence is likely to continue to rise 2,3 . Although a cure is not currently available, various therapies are available to induce, and then maintain, disease remission and prevent disease complications.…”

Section: Introductionmentioning

confidence: 99%

Patient perceptions of current and potential inflammatory bowel disease diagnostic and monitoring tests

Keenan

2022

Internal Medicine Journal

Self Cite

View full text Add to dashboard Cite

Background Less invasive inflammatory bowel disease (IBD) tests are increasingly being incorporated into clinical practice as adjuncts to endoscopy to monitor disease activity and guide optimal care. Little is known about patient perspectives of these tests. Aims To assess patient perspectives of the current IBD tests and potential future tests, such as saliva, urine or breath. Methods New Zealand adults with IBD were invited to complete an anonymous online survey. Experiences relating to blood or faecal tests, medical imaging (abdominal ultrasound, abdominal computed tomography and magnetic resonance enterography) and colonoscopy were collected. Results Of the 117 completed surveys, 112 respondents provided background details. The majority (85%) of participants were female and 88% were aged <55 years with a mean disease duration of 8.98 years. General blood tests were reported as the most prescribed, completed, comfortable test and the least worrying test results. Imaging tests were reported as the least ordered and the most refused tests. Colonoscopy was rated as the least comfortable and generated the most worry. Test explanations by a referring clinician significantly impacted on respondents' levels of understanding across all tests, but did not affect the level of worry when receiving test results. Saliva, blood and breath tests were chosen as the most preferred disease monitoring tests. Conclusions Patients with IBD preferred any tests less invasive than colonoscopy. An explanation by referring doctor enhanced patients' understanding, but did not necessarily influence their level of comfort or worry.

show abstract

Prospective Incidence of Paediatric Inflammatory Bowel Disease in New Zealand in 2015

Cited by 20 publications

References 32 publications

Current global trends in the incidence of pediatric-onset inflammatory bowel disease

Current global trends in the incidence of pediatric-onset inflammatory bowel disease

Diagnostic Delay in Paediatric Inflammatory Bowel Disease—A Systematic Investigation

Patient perceptions of current and potential inflammatory bowel disease diagnostic and monitoring tests

Contact Info

Product

Resources

About